Keyword: Juno Therapeutics

T cell

FDA clears Juno to resume CAR-T trial

Juno Therapeutics was up by about 25% in after-hours trading on news that the FDA has already given it permission to resume the Phase II trial for its JCAR015 that it halted last week.